Jaroslaw Maciejewski, MD, PhD

216.444.6833

Jaroslaw Maciejewski, MD, PhD

Appointed: 2001

Jaroslaw Maciejewski, MD, PhD
Department: Translational Hematology and Oncology Research
Department Chair
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6833
DeskDesk:216.445.5962
WorkFax:216.636.2498
Jaroslaw Maciejewski, MD, PhD
Department: Hematology and Oncology
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6833
DeskDesk:216.445.5962
WorkFax:216.636.2498
Jaroslaw Maciejewski, MD, PhD
Department: Clinical Pathology
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6833
DeskDesk:216.445.5962
WorkFax:216.636.2498
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Jaroslaw P. Maciejewski, MD, PhD, FACP, is Staff Physician in the Cleveland Clinic Department of Hematologic Oncology and Blood Disorders and is board certified in hematology and internal medicine. He is also Chairman of the Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute and has an academic rank of Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Recognized for his scholarly achievement in biomedical research, Dr. Maciejewski is an elected member of The American Society for Clinical Investigation (ASCI).

His clinical areas of expertise include bone marrow failure syndromes (including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria), and myeloid malignancies. His research deals with the molecular pathogenesis of these disorders and deals with various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology. He has developed multiple whole genome scanning technologies for laboratory and diagnostic use, including SNP-arrays, methylation arrays and viral chips.

Dr. Maciejewski attended medical school at the Medical School Charite, Humboldt University, Berlin, Germany receiving his medical degree and doctorate from the Institute for Medical Immunology at Humboldt University Medical School. He completed his internal medicine residency at the University of Nevada, School of Medicine in Reno, NV and Hematology Fellowship at the National Institutes of Health Medical Center, Bethesda, MD. He also completed his postdoctoral research fellowship at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD where he later served as Staff Scientist before joining Cleveland Clinic in 2001 as Staff Physician and Section Head of Experimental Hematology. In January 2009, Dr. Maciejewski was appointed Chairman of the newly created Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute.

Dr. Maciejewski has a distinguished track record in research relating to the hematology and pathophysiology of hematologic diseases including bone marrow failure syndromes (BMFS). His extensive list of publications (over 150 peer-reviewed journal articles and book chapters) demonstrates his success as an accomplished translational physician-scientist. As Principal Investigator, Dr. Maciejewski has acquired notable grant funding from federal, foundation and industry sponsors since joining Cleveland Clinic in 2001. His most recent achievement is a $1.9 million grant award from the National Institutes of Health’s Transformative R01 program. The Transformative R01 grants are awarded for "exceptionally innovative, high-risk and unconventional research projects that have the potential to create or overturn fundamental paradigms.” This funding will help support Dr. Maciejewski’s research related to whether viruses could be the cause of certain types of bone marrow cancers and other blood disorders. In addition to bench translational research, he leads the Cleveland Clinic Bone Marrow Failure Program that conducts various clinical trials based on investigator-initiated protocols involving the application of targeted immune therapies.

He serves on the Medical Advisory Board of the International Aplastic Anemia and Myelodysplastic Syndrome Foundation, the editorial board of Blood and has also been a reviewer on various study sections for the NIH. He served on the International Scientific Committee at the 10th International Symposium on Myelodysplastic Syndromes held in Patras, Greece in 2009 and was presented with the Celgene Young Investigator Award for Clinical Research in Hematology at the 50th Annual ASH Meeting in San Francisco in 2008. Dr. Maciejewski is also committed to his role as mentor. His K24 Career Development award from the NIH has enabled him to actively continue mentoring medical students, postdoctoral/clinical fellows and junior faculty through his Bone Marrow Failure Training Program for physician-scientists.

Professional Highlights

  • Department Chair, Translational Hematology and Oncology Research
  • Member, Medical Advisory Board, Aplastic Anemia and MDS International Foundation
  • Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Education & Fellowships

Fellowship - National Heart, Lung and Blood Institute
Hematology
Bethesda, MD USA
2000
Residency - University of Nevada School of Medicine
Internal Medicine
Reno, NV USA
1998
Doctorate - Humboldt University Berlin, Medical School (Charite)
Immunology
Berlin Germany
1990
Medical School - Humboldt University Berlin, Medical School (Charite)
Berlin Germany
1988

Specialty Interests

Bone marrow failure syndromes including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria, autoimmune neutropenia, pure red cell aplasia and other refractory anemias, cytopenias, acute lymphocytic leukemia

Awards & Honors

  • American Society of Clinical Investigation
  • America's Best Doctors
  • Fellow in FACP since 7/1/09 from the Ohio Chapter

Memberships

  • American Society of Clinical Investigation
  • American Medical Association
  • American Society of Hematology

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/5/2014, Dr. Maciejewski has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Maciejewski received fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Celgene Corporation
  • Eisai Co., Ltd.
  • ICON plc

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
  • German
  • Polish
  • Russian
Cleveland Clinic Mobile Site